Kyverna Therapeutics
Clinical trials sponsored by Kyverna Therapeutics, explained in plain language.
-
Engineered immune cells target root cause of debilitating neurological disease
Disease control OngoingThis study is testing whether a therapy called KYV-101 can help people with Stiff Person Syndrome (SPS) who haven't improved with other treatments. KYV-101 uses a patient's own immune cells, which are modified in a lab to find and remove the specific B cells thought to drive the …
Phase: PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Personalized cell therapy tested for Hard-to-Treat scleroderma
Disease control OngoingThis early-stage study is testing a new personalized cell therapy called KYV-101 for adults with active, diffuse systemic sclerosis (scleroderma). The therapy involves modifying a patient's own immune cells to target and remove certain B-cells thought to drive the disease. The ma…
Phase: PHASE1, PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Revolutionary cell therapy tested for Tough-to-Treat lupus kidney damage
Disease control OngoingThis early-stage study is testing a new therapy called KYV-101 for adults with severe lupus nephritis, a serious kidney disease caused by lupus, that hasn't improved with standard treatments. The therapy involves collecting a patient's own immune cells, modifying them in a lab to…
Phase: PHASE1, PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Groundbreaking cell therapy trial targets devastating lupus kidney damage
Disease control OngoingThis early-stage study is testing a new, personalized cell therapy called KYV-101 for adults with severe lupus nephritis, a serious kidney disease caused by lupus, that hasn't responded to other treatments. The therapy involves modifying a patient's own immune cells to target and…
Phase: PHASE1, PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC